Difficulty: Medium
Average Score: 80%
Practice
The second generation sulfonylurea hypoglycaemics differ from the first generation one in that they
Correct answer
A
Rationale
In this question about second-generation sulfonylurea hypoglycemic drugs, the correct answer is A) Are more potent. This is because second-generation sulfonylureas, such as glimepiride and glipizide, have a higher potency compared to first-generation drugs like chlorpropamide and tolbutamide. This increased potency allows for a lower dosage to achieve the desired therapeutic effect, reducing the risk of side effects.
Option B) Are longer acting is incorrect because the duration of action varies among different sulfonylureas within both first and second generations. Some first-generation drugs have longer durations of action compared to certain second-generation drugs.
Option C) Do not lower blood sugar in nondiabetic subjects is incorrect as sulfonylureas work by stimulating insulin release from pancreatic beta cells, regardless of the individual's diabetic status. Therefore, they would lower blood sugar in both diabetic and nondiabetic subjects.
Option D) Are less prone to cause hypoglycemic reactions is incorrect because second-generation sulfonylureas are actually associated with a higher risk of hypoglycemia compared to first-generation drugs due to their increased potency and longer duration of action.
In an educational context, understanding the differences between first and second-generation sulfonylureas is crucial for healthcare professionals managing patients with diabetes. Knowing the specific characteristics of each generation of drugs helps in making informed decisions regarding drug selection, dosing, monitoring for side effects, and managing potential complications such as hypoglycemia. This knowledge ultimately contributes to optimizing patient care and outcomes in diabetic individuals.
Option B) Are longer acting is incorrect because the duration of action varies among different sulfonylureas within both first and second generations. Some first-generation drugs have longer durations of action compared to certain second-generation drugs.
Option C) Do not lower blood sugar in nondiabetic subjects is incorrect as sulfonylureas work by stimulating insulin release from pancreatic beta cells, regardless of the individual's diabetic status. Therefore, they would lower blood sugar in both diabetic and nondiabetic subjects.
Option D) Are less prone to cause hypoglycemic reactions is incorrect because second-generation sulfonylureas are actually associated with a higher risk of hypoglycemia compared to first-generation drugs due to their increased potency and longer duration of action.
In an educational context, understanding the differences between first and second-generation sulfonylureas is crucial for healthcare professionals managing patients with diabetes. Knowing the specific characteristics of each generation of drugs helps in making informed decisions regarding drug selection, dosing, monitoring for side effects, and managing potential complications such as hypoglycemia. This knowledge ultimately contributes to optimizing patient care and outcomes in diabetic individuals.